Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the agreement, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, and generation of new agreements for the avai...
Product Name : Spikevax
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
Details : Agreement with Adium Pharma will support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina.
Product Name : Spikevax
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin America
Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Product Name : Yondelis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 27, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement